Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
复制标题
99mTc 标记的 PSMA-SPECT/CT 成像对生化复发的前列腺癌患者的评估。
DOI：
10.4103/1008-682x.192638
复制
发表时间：
2017-05
影响因子：
2.9
通讯作者：
Ye DW
中科院分区：
文献类型：
--
作者：
Su HC;Zhu Y;Ling GW;Hu SL;Xu XP;Dai B;Ye DW
使用传统的成像方式，很难检测到复发性病变的前列腺癌患者谁经历了生化复发，特别是在低前列腺特异性抗原（PSA）水平的患者。我们回顾性分析了50例经组织病理学证实的前列腺癌患者的资料，这些患者在30天内接受了99 mTc标记的前列腺特异性膜抗原（PSMA）单光子发射计算机断层扫描（SPECT）/计算机断层扫描（CT）、磁共振成像（MRI）和骨扫描。PSMA-SPECT/CT对39例转移灶的检出率（78.0%）高于骨扫描（34.0%）和MRI（40.0%）。PSMA SPECT/CT显像对骨和淋巴结转移的诊断效率（50.0%和42.0%）优于骨扫描（34.0%和0.0%）和MRI（24.0%和20.0%）。在血清PSA水平≤1 ng ml−1、1-4 ng ml−1、4-10 ng ml −1和>10 ng ml−1时，PSMA-SPECT/CT的检出率更高。Gleason评分、PSA水平和转移灶的示踪肿瘤/背景比值之间无相关性。在PSMA-SPECT/CT成像的帮助下，31例患者改变了治疗策略，这可能提高了他们的临床结局。总之，PSMA-SPECT/CT成像可以检测到更多的转移性病变，并实现更高的检测率比传统的成像方式在不同的血清PSA水平的前列腺癌患者谁经历了生化复发。
Using conventional imaging modalities, it is difficult to detect recurrent lesions in prostate cancer patients who have undergone biochemical relapse, especially in patients with low prostate-specific antigen (PSA) levels. We retrospectively reviewed the files of fifty patients with histopathologically confirmed prostate cancer who underwent 99mTc-labeled prostate-specific membrane antigen (PSMA) single-photon emission computed tomography (SPECT)/computed tomography (CT), magnetic resonance imaging (MRI), and bone scan within a 30-day period. PSMA-SPECT/CT indicated metastatic lesions in 39 patients and had a higher detection rate (78.0%) than bone scan (34.0%) or MRI (40.0%). The diagnostic efficiency of PSMA-SPECT/CT imaging for bone and lymph node metastases (50.0% and 42.0%) was better than bone scan (34.0% and 0.0%) or MRI (24.0% and 20.0%). PSMA-SPECT/CT provided a higher detection rate at serum PSA levels of ≤1 ng ml−1, 1–4 ng ml−1, 4–10 ng ml−1, and >10 ng ml−1. No correlation was found between Gleason score, PSA level, and the tracer tumor/background ratio of metastatic lesions. With the aid of PSMA-SPECT/CT imaging, the therapeutic strategy was changed for 31 patients, and this may have enhanced their clinical outcome. In conclusion, PSMA-SPECT/CT imaging could detect more metastatic lesions and achieve a higher detection rate than conventional imaging modalities at different serum PSA levels in prostate cancer patients who had undergone biochemical relapse.